神经轴突导向因子2在恶性神经胶质瘤中表达及其与患者临床病理特征和生存率的影响

Expression of neuronal guidance factor netrin-2 in malignant glioma and its relationship with clinicopathological features and survival rate

目的探讨神经轴突导向因子2(Slit2)在恶性神经胶质瘤组织中的表达及与患者临床病理特征和生存率的关系。方法选取河南省商丘市第一人民医院和郑州大学第一附属医院2016年9月到2019年9月收集的104例神经胶质瘤和癌旁组织作为研究对象,采用免疫组织化学检测Slit2蛋白表达,分析Slit2表达水平与患者临床病理特征和预后的关系。采用χ^(2)检验分析Slit2与临床病理特征的关系,生存分析采用Kaplan-Meier生存曲线,多因素采用Logistic回归分析。结果神经胶质瘤组织中Slit2蛋白表达阳性率[19.23%(20/104)]明显低于癌旁组织[80.77%(84/104)],差异有统计学意义(χ^(2)=17.120,P<0.05)。Ⅰ~Ⅱ级患者神经胶质瘤组织Slit2蛋白表达阳性率[38.10%(16/42)]明显高于Ⅲ~Ⅳ级患者神经胶质瘤组织Slit2蛋白表达阳性率[6.45%(4/62)],差异有统计学意义(χ^(2)=11.109,P<0.05)。中高分化患者神经胶质瘤组织Slit2蛋白表达阳性率[28.13%(18/64)]明显高于低分化患者神经胶质瘤组织Slit2蛋白表达阳性率[2.50%(2/40)],差异有统计学意义(χ^(2)=9.902,P<0.05)。Slit2高表达组患者生存率[55.00%(11/20)]明显高于Slit2低表达患者生存率[32.14%(27/84)],差异有统计学意义(χ^(2)=8.771,P<0.05)。多因素回归分析,结果显示临床分期、分化程度和Slit2表达水平均是影响神经胶质瘤患者总生存率的独立危险因素(P<0.05)。结论 Slit2蛋白在神经胶质瘤组织中呈低表达,与患者临床分期和分化程度以及总生存率密切相关。

Objective To investigate the expression of Slit2 in malignant glioma and its relationship with clinicopathological features and survival rate.Methods 104 cases of glioma and adjacent tissues collected in our hospital from September 2016 to September 2019 were selected as the research objects.The expression of Slit2 protein was detected by immunohistochemistry,and the relationship between Slit2 expression level and clinicopathological features and prognosis was analyzed.Chi square test was used to analyze the relationship between Slit2 and clinicopathological features.Kaplan Meier survival curve was used for survival analysis,and Logistic regression was used for multiple factors.Results The positive rate of Slit2 protein expression in glioma tissues[19.23%(20/104)]was significantly lower than that in adjacent tissues[80.77%(84/104),χ^(2)=17.120,P<0.05].The positive rate of Slit2 protein expression in gliomas of gradeⅠ-Ⅱpatients[38.10%(16/42)]was significantly higher than that of gliomas of gradeⅢ-Ⅳpatients[6.45%(4/62),χ^(2)=11.109,P<0.05].The positive rate of Slit2 protein expression in medium and high differentiation gliomas(18/64,28.13%)was significantly higher than that in poorly differentiated gliomas[2.50%(2/40),χ^(2)=9.902,P<0.05].The survival rate of patients with high Slit2 expression group[55.00%(11/20)]was significantly higher than that of patients with low Slit2 expression[32.14%(27/84),χ^(2)=8.771,P<0.05].Multivariate regression analysis showed that clinical stage,degree of differentiation and Slit2 expression were independent risk factors affecting the overall survival rate of glioma patients(P<0.05).Conclusion Slit2 protein is low expressed in glioma,which is closely related to clinical stage,differentiation and overall survival rate.